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Exome Sequencing Reveals Common and Rare 
Variants in F5 Associated With ACE Inhibitor 
and Angiotensin Receptor Blocker–Induced 
Angioedema
Cyrielle Maroteau1,* , Moneeza Kalhan Siddiqui1, Abirami Veluchamy1, Fiona Carr1, Myra White1,  
Andrew J. Cassidy2, Ekaterina V. Baranova3, Eva R. Rasmussen4,5, Niclas Eriksson6,7 , Katarzyna M. Bloch8,  
Nancy J. Brown9, Anette Bygum5, Par Hallberg6 , Malgorzata Karawajczyk10, Patrik K. E. Magnusson11,  
Qun-Ying Yue12, Ann-Christine Syvänen13, Christian von Buchwald4, Ana Alfirevic8,  
Anke H. Maitland-van der Zee3,14, Mia Wadelius6 , and Colin N. A. Palmer1 on behalf of PREDICTION-ADR
Angioedema occurring in the head and neck region is a rare and sometimes life-threatening adverse reaction 
to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). Few studies have 
investigated the association of common variants with this extreme reaction, but none have explored the combined 
influence of rare variants yet. Adjudicated cases of ACEI-induced angioedema (ACEI-AE) or ARB-induced angioedema 
(ARB-AE) and controls were recruited at five different centers. Sequencing of 1,066 samples (408 ACEI-AE, ARB-AE, 
and 658 controls) was performed using exome-enriched sequence data. A common variant of the F5 gene that 
causes an increase in blood clotting (rs6025, p.Arg506Gln, also called factor V Leiden), was significantly associated 
with both ACEI-AE and ARB-AE (odds ratio: 2.85, 95% confidence interval (CI), 1.89–4.25). A burden test analysis 
of five rare missense variants in F5 was also found to be associated with ACEI-AE or ARB-AE, P = 2.09 × 10−3. A 
combined gene risk score of these variants, and the common variants rs6025 and rs6020, showed that individuals 
carrying at least one variant had 2.21 (95% CI, 1.49–3.27, P = 6.30 × 10−9) times the odds of having ACEI-AE or 
ARB-AE. The increased risk due to the common Leiden allele was confirmed in a genome-wide association study 
from the United States. A high risk of angioedema was also observed for the rs6020 variant that is the main 
coagulation defect-causing variant in black African and Asian populations. We found that deleterious missense 
variants in F5 are associated with an increased risk of ACEI-AE or ARB-AE.
Received February 20, 2020; accepted May 8, 2020. doi:10.1002/cpt.1927
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Patients taking drugs acting on the renin-angiotensin sys-
tem to manage hypertension can develop adverse drug reac-
tions. Few studies have investigated the association of common 
variants with extreme reaction, such as angioedema of the face, 
lip, and pharynx, but none have explored the influence of rare 
variants yet.
WHAT QUESTION DID THIS STUDY ADDRESS?
 We confirm that genetic variations (common and rare) 
are involved in this serious adverse drug reaction and report 
the implication of another gene from the coagulation sys-
tem (factor V) in the development of angioedema induced by 
angiotensin-converting enzyme (ACE) inhibitor or angiotensin 
receptor blocker (ARB) therapy.
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 This study presents new common and rare variants in the 
F5 gene associated with an increased risk of developing an angi-
oedema when under antihypertensive drugs.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 These findings have important clinical implications for the 
prevention of ACE inhibitor and ARB-induced angioedema. 
We propose a new genetic marker which may inform personal-
ized antihypertension therapy.
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Hypertension is a widespread health problem that is present in a quar-
ter of the Western adult population. Drugs acting on the renin-an-
giotensin system are commonly prescribed to manage this condition. 
Even though angiotensin-converting enzyme inhibitors (ACEIs) and 
angiotensin receptor blockers (ARBs) are generally well tolerated and 
effective, some patients experience adverse drug reactions (ADRs) 
during treatment.1,2 A serious ADR is angioedema of the tongue, 
cheeks, lips, or pharynx, characterized by swelling of the reticular der-
mis and subcutaneous skin layers or mucosa. Angioedema induced 
by ACEIs or ARBs can sometimes be life threatening or even lethal, 
and it usually occurs during the first months of therapy but may also 
appear after several years. The incidence of angioedema is estimated 
to be 0.2–0.7% for ACEIs and 0.03% for ARBs,3,4 with a higher rate 
in patients of African descent and in those with affected relatives.5,6
To understand the genetic underpinnings of rare ADRs to 
statins and ACEIs or ARBs, an international multicenter project, 
Personalization of Treatment In Cardiovascular drugs using next 
generation sequencing (PREDICTION-ADR) was established in 
2013. Recruitment of patients was facilitated by the development 
of standardized phenotypes for statin myopathy and angioedema 
induced by ACEIs or ARBs with inputs from experts in the field.7,8 
PREDICTION-ADR has established novel genetic biomarkers in 
the pharmacogenetics of statin intolerance.9
In previous studies, genetic variants in the bradykinin path-
way, bradykinin-degrading enzyme aminopeptidase P gene 
(XPNPEP2)10,11 and type 2 bradykinin receptor gene (BDKRB2), 
have been associated with ACEI-induced and ARB-induced cough 
and angioedema. Other genes, serpin family E member 1 gene 
(SERPINE1) and the coagulation factor XII gene (F12), have been 
associated with hereditary angioedema. None of them have been 
significantly replicated in the only two published genome-wide as-
sociation studies, where intronic variants in the calcium-activated 
potassium channel subunit alpha-1 (KCNMA1) were significantly 
associated with ACEI-AE in a Swedish cohort (SWEDEGENE 
study)12 and a variant of the protein kinase C theta gene (PRKCQ) 
tended to be protective in a European American cohort.13
In addition, studies have reported that the risk of ACEI-AE 
varies according to ethnicity and gender, with women and black 
Africans being more likely to develop this particular ADR5,6,14–18.
Although previous studies assessed common variants in the asso-
ciation between ACEI and angioedema,12,13 they have had limited 
success in identifying a genetic basis for this ADR. This study used 
next-generation sequencing technology to assess the influence of 
low frequency variants with intermediate penetrance and higher 
relative risks and combined association with common variants 
with ACEI-AE and ARB-AE, using cases and controls recruited 
in Scotland, Sweden, Denmark, the Netherlands, and England. 
We report novel results from both analyses of common and rare 
variants. Replication was performed in a cohort from the United 
States, and we developed a gene risk score (GRS) for angioedema 
using common and rare variants of F5.
METHODS
Study population and phenotype definitions
PREDICTION-ADR. In the PREDICTION-ADR project, cases of 
ACEI-AE and ARB-AE and controls were recruited at five different cen-
ters: Uppsala (Sweden), Dundee (Scotland), Utrecht (the Netherlands), 
Liverpool (England) and Copenhagen (Denmark). Details are available 
in the Supplementary Materials (Table S1). All study sites obtained ap-
proval from their respective institutional review board or ethics commit-
tee. All the recruited cases were adjudicated by a specialist in allergology. 
Individuals failing adjudication were excluded.
Cases. Cases of ACEI-AE and ARB-AE were defined according to the 
phenotype standardization published by Wadelius et al., i.e., swelling in 
the head and neck region without any other likely cause (e.g., allergy or 
hereditary angioedema).7
In Sweden, 252 patients with ACEI-AE or ARB-AE were selected 
from the Swedegene biobank,19 which is a nationwide collection of ADR 
cases. Most cases had been recruited among patients reported to the ADR 
registry at the Swedish Medical Products Agency, but a minority were 
referred directly from collaborating clinicians. In Denmark, 63 patients 
with ACEI-induced or ARB-induced angioedema were referred by phy-
sicians from seven hospitals and by a collaborating general practitioner.
In Scotland, 15 cases were recruited via electronic medical records 
with the Scottish Health Registry (SHARE),20 as well as the Genetics 
of Scottish Health Registry for Adverse Drug Reactions (GoSHARE-
ADR) website. Individuals who had either stopped using ACEIs or had 
switched from an ACEI to an ARB with an antihistamine prescription 
in a 30-day window from the last ACEI prescription were selected. Each 
case was then individually examined for the most accurate summary 
of events and adjudicated as being “highly probable” candidates for 
ACEI-AE. In England, 18 cases were recruited using electronic medical 
records via the UK clinical Practice Research Datalink (CPRD), follow-
ing the same steps as previously described for Scotland.
Finally, in the Netherlands, 72 cases were selected from the Dutch 
PHACE study.
Controls. ACEI-tolerant controls presented no relevant adverse effects 
while on therapy. Controls were matched for age and sex with cases of the 
same study site whenever possible.
In total 271 Swedish population-controls were selected from the 
TwinGene Biobank.21 The controls had all collected at least five prescrip-
tions for an ACEI over at least 1 year according to the Swedish Prescribed 
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Drug Register. They had never been diagnosed with angioedema or lar-
ynx edema according to the Swedish National Patient Register. Using the 
same criteria, 20 ACEI-treated control subjects were enrolled by collabo-
rating physicians in Denmark. Seventy-two Dutch controls were selected 
from the Utrecht Cardiovascular Pharmacogenetics study (UCP) using 
the same criteria as above. One hundred fifteen Scottish and 199 English 
patients were selected if they were ACEI users for over 2 years with no 
switching to ARB or discontinuation, via the same databases as the cases.
Replication cohort: the Vanderbilt study. Genome-wide association 
study results from the Vanderbilt study were used for replication.22 Data 
were available for 438 Europeans and 214 black Americans. Population 
demographic of the genotyped Vanderbilt population has been previ-
ously described.
Patients with angioedema were selected by searching electronic med-
ical records followed by their primary physician confirmations or by 
direct referral from physicians. Patients with hereditary angioedema 
were discarded. Cases were defined as presenting with swelling of the 
lips, pharynx, larynx, or face while taking an ACEI therapy. Controls 
were defined as patients who had been treated with an ACEI for at least 
six months without developing angioedema. Cases and controls were 
matched with respect to sex, race, and smoking status. To confirm their 
medical histories, all patients were interviewed by a research nurse or a 
physician. The study was approved by Vanderbilt’s Institutional Review 
Board, and informed consent was obtained from all participants. Only 
Europeans were considered for replication in our study.
Whole-exome sequencing
Whole-exome sequencing was undertaken in laboratories in Liverpool 
and Dundee, UK and Uppsala, Sweden. DNA was extracted from blood 
or saliva samples.
Library preparation and capture. Sequencing of 1,066 samples (408 
ACEI-AE, 658 controls) was performed using exome-enriched sequence 
data. SureSelect QXT, XT, and XT2 reagents (Agilent Technologies, 
Wokingham, UK) were used to perform fragmentation, end-repair, 
A-addition, and adaptor ligation reactions to generate Illumina-
compatible sequencing libraries. Hybridization capture enrichment of 
whole-genome libraries was performed using the SureSelect v5 all-exon 
probe set, according to the manufacturer’s recommendations. Genomic 
DNA was quantified using a Qubit double-stranded DNA high sensitiv-
ity assay kit and Qubit Fluorometer (Life Technologies, Carlsbad, CA), 
using 750 ng for both XT and XT2, and 50 ng for QXT of genomic DNA 
as input material. The size of the final pool was assessed on a Bioanalyzer 
high sensitivity DNA chip, and the DNA concentration was determined 
by Qubit double-stranded DNA high sensitivity assay.
Sequencing. Sequencing was conducted on an Illumina (San Diego, 
CA) Nextseq500 (Dundee) and a Hiseq2500 (Uppsala and Liverpool). 
Equimolar aliquots of 8–12 postenrichment libraries (mixing cases and 
controls) were pooled before sequencing using version 2 TruSeq chem-
istry (Illumina) on a Nextseq500 and 8–96 libraries on version 4 for 
Hiseq2500. Respectively 28, 12 and four sequencing runs were carried out 
in Dundee, Liverpool and Upsala, with 8–12 samples per lane generating 
2 × 151 base pair (bp) (Nextseq500) or 2 × 215 bp (Hiseq2500) paired-
end reads. Paired-end sequence reads were analyzed through an in-house 
pipeline (University of Dundee), which gathers preprocessing, demulti-
plexing, alignment, duplicate removal, variant discovery, and annotation 
(pipeline description provided in the Supplementary Materials).
A presequencing of eight controls was done previously on the three 
different sequencers to ensure good concordance. Details of sequencing 
quality can be found Tables S2 and S3.
Statistical analysis
Variant filtering and principal component analysis. Quality control 
filtering was performed on the variant call format using VCFtools.23 
Only high-quality single nucleotide polymorphisms (SNPs) (at least 20-
fold coverage, quality score of at least 60, a genotype quality score of at 
least 20, a quality by depth score of at least 2, a mapping quality score of at 
least 40, a read rank sum score > −3, and a mapping quality rank of score 
greater than −10), with a call rate of > 98% as well as not showing devia-
tion from Hardy-Weinberg equilibrium (P < 1 × 10−6 for deviation) and 
present in at least one individual were kept for the analysis. Each sam-
ple was similarly checked, and those with a poor sequencing success rate 
(< 95%) or having outlying genetic ancestry (defined by being more than 
Figure 1 Manhattan plot adjusted by gender and genetic principal components 1–10. The red line corresponds to the genome-wide 
significance threshold 5.6 × 10-6 (Bonferroni correction). One SNP is above the red line, on chromosome 1, but no clear peak can be seen. 
SNP, single nucleotide polymorphism.
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six standard deviations (SDs) from the mean on principal-component 
analysis) were excluded from further analysis (Figures S1 and S2).
Single variant analysis of common variants minor allele frequency > 1%. 
Analysis was performed using PLINK/SEQ.24 Single-variant association 
was performed on samples using a logistic regression test under the as-
sumption of different genetic models (dominant, additive, and recessive), 
correcting for the covariates sex, center, sequencing batch, and 1–10 prin-
cipal components. The exome-wide significance P value threshold was set 
to P < 1 × 10−6 to correct for multiple testing. QQplot and Manhattan 
plot are presented Figure S3 and Figure 1.
Rare variant analysis (minor allele frequency < 1%). Gene-based as-
sociations were performed with RVtest25 using a sequence kernel associa-
tion test – optimal (SKAT-O)26 and burden test,27 taking into account the 
same covariates as for the analysis of common variants. Among the 38,642 
genes fulfilling all quality control filters, 7,143 genes presenting variants re-
sulting in a stop missense/splicing/gain/loss (13,016 variants) were selected 
for analyses. The significance P value threshold was set to P < 7 × 10−6.
Meta-analysis. A fixed-effects meta-analysis on results from the 
PREDICTION-ADR and Vanderbilt cohorts was performed using 
GWAMA.28 Results are presented in a forest plot using the metafor 
package in R.29,30
Development of the F5 gene score. All nonsynonymous F5 variants 
(common and rare) were combined into a gene score computed in SAS 
9.3 (SAS Institute, Cary, NC) based on the PREDICTION-ADR data. 
Variants in the F5 gene were combined using the weighted GRS calcu-
lation method described by Zhou et al.31 Allele frequency differences 
were assessed for cases and controls. Linear regression was used to test the 
association between individuals carrying at least one deleterious variant 
against none and the angioedema phenotype. Center, sequencing batch, 
and 1–10 principal components, as well as covariates associated with in-
tolerance such as sex and age were added to the model.
RESULTS
Baseline characteristics of ACEI-induced angioedema cases
Baseline characteristics of cases and controls in the 
PREDICTION-ADR cohort are shown in Table 1. Cases and 
controls were matched for potential risk factors for development 
of angioedema (time under medication, sex, dose, and use of in-
teracting comedication). The sex distribution was 47% female 
for ACEI-AE, and 50% for ARB-AE. A majority had presented 
with a first occurrence of angioedema (72%). The mean time 
under medication was 3.44 years for ACEI, with doses ranging 
from 6.11  mg/day to 20.41  mg/day, and the mean time under 
medication with an ARB was 2.73  years, with doses ranging 
from 8 mg/day to 125 mg/day. The most commonly suspected 
ACEI was enalapril (65.8% of all cases), and the most commonly 
suspected ARB was losartan (6.6% of all cases), Table 2. A total 
of 2% of the ACEI-AE cases and 7% of the ARB-AE cases stated 
that a family member had experienced angioedema from these 
medications.
Approximately 23% of the study population had type 2 diabetes, 
mostly due to the recruitment from the Genetics of Diabetes and 
Audit Research Tayside Study (GoDARTS) in Scotland.
After removing samples and markers failing quality control, 
1,033 individuals (387 cases, 646 controls) remained with 
178,995 variants. The average per individual genotyping rate 
was 98.9%. We then defined two sets of data based on the minor 
allele frequency (MAF). SNPs with MAF  <  1% were used for 
rare variant analysis (128,157 SNPs), whereas common SNPs 
with a MAF > 1% were used for single variant analysis (50,838 
SNPs).
Table 1 Characteristics of all angioedema cases and ACEI-treated controls included in the PREDICTION-ADR project
Variables ACEI-AE (n = 343) ARB-AE (n = 44) ACEI-treated controls (n = 646)
Time under medication (years) (mean (SD)) 3.44 (3.96) 2.73 (4.01) NA
Dose (mg/day) (mean (SD)) 13.3 (7.15) 63.01 (69.7) NA
Age at event (years) (mean (SD)) 64.9 (9.77) 64.2 (9.34) NA
BMI (kg/m2)a (mean (SD)) 27.4 (4.43) 27.5 (4.95) 30.4 (7.5)
Alcohol consumption (units/week) (mean (SD)) 5.56 (19.9) 4.55 (4.89) NA
Sex: female (%) 47.4 50 38.7
First time of angioedema (%) 71.9 NA NA
Family angioedema (%) 1.87 6.81 NA
Comedication (%) 95.3 97.7 NA
Diabetes (%) 23.9 22.7 31.7
Smoking (%) 76.06 4.54 NA
Radiation therapy (%) 0.39 0 NA
UV treatment (%) 0.77 0 NA
ACEI, angiotensin-converting enzyme inhibitor; AE, adverse event; ARB, angiotensin receptor blocker; NA, not available; UV, ultraviolet.
aBody Mass Index (BMI) only available for about 2/3 of the controls.
Table 2 Reported causative drugs in the PREDICTION-ADR 
angioedema cases





ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor 
blocker.
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Association between ACEI-induced angioedema and factor 
V Leiden
With a P value of 1.53  ×  10−7, F5 rs6025 (factor V Leiden) 
passed exome-wide significance in the single variant analysis 
(P < 1 × 10−6) (Figure S3 and Figure 1). Carriers of the p.534Gln 
variant had 2.85 (95% confidence interval (CI), 1.89–4.25) times 
the odds of having angioedema compared with individuals homo-
zygous for p.Arg534 (Table 3), in a model adjusted for sex, age, 
sequencing batch, study center, and 10 principal components. The 
top 20 hits are available in Table S4.
Meta-analysis of results
A large risk effect for the p.534Gln variant was also observed 
in the Vanderbilt study (odds ratio (OR): 1.68; 95% CI, 0.639–
4.40) in a model adjusted for age and sex. While this replica-
tion cohort was not individually significant, a meta-analysis 
of the observed effects across PREDICTION-ADR and the 
Vanderbilt study revealed that overall, carriers of p.534Gln 
have 2.63 (95% CI, 1.81–3.83) times the odds of experienc-
ing ACEI-AE compared with p.Arg534 homozygotes (P value 
3.7 × 10−7) (Figure 2).
Association between ACEI-induced angioedema and F5 rare 
variants
The top significant genes found with the burden test analysis 
are reported in Table  S5. QQplots for both burden test and 
SKAT-O are presented in respectively Figures S4 and S5.
Five nonsynonymous rare variants were found in the F5 locus: 
rs200157005, rs149389480, rs143509841, rs140530655, and 
chr1:169529903 (Table  4). These variants, two deleterious and 
three protective, were analyzed with a SKAT-O model and found 
to be nominally significant, P value = 0.0021.
F5 GRS
A total of 11 common and rare nonsynonymous variants were 
found in the F5 locus (Table 3). The variants rs6025, rs200157005, 
rs149389480, rs143509841, rs140530655, and chr1:169529903 
were associated with ACEI-AE and ARB-AE in our study. Using 
the F5 genotype risk score we created from those SNPs, we show 
that angioedema is strongly associated with any F5 GRS levels 
against none, with a P value of 6.30 × 10−9.
Moreover, when considering rs6020, individuals carrying at least 
one F5 deleterious variant had 2.21 (95% CI, 1.49–3.27) times the 
odds of having ACEI-AE or ARB-AE compared with noncarriers 
in a model adjusted for age, sex, center, batch, and 1–10 principal 
components (Table 5).
DISCUSSION
This is the largest whole-exome sequencing study of ACEI-AE and 
ARB-AE. We found that common and rare F5 gene variants were 
associated with ACEI-AE and ARB-AE. Of these variants, factor 
V Leiden (rs6025) exhibited the strongest association. Association 
with angioedema was even higher when rs6025 was combined with 
rare F5 variants showing that both common and rare variants in-
fluence risk of angioedema. Replication of the GRS association was 
not possible in the Vanderbilt study due to the absence of rare vari-
ants in the genotyping file (no genotype when MAF < 1% or qual-
ity of imputation < 0.8). Moreover, considering that ACEI-AE and 
ARB-AE might be two different diseases, we studied the associa-
tion without the 44 ARB-AE cases. We found the same association 
Table 3 Distribution of F5 p.Arg534Gln genotypes by adjudicated ACEI-AE and ARB-AE status
Group Arg534 only (n) 534Gln carriers (n) Total (n) Association
ACEI-AE/ARB-AE 326 61 387 Odds ratio = 2.85
ACEI/ARB controls 609 37a 646 95% CI, 1.89–4.25
Total 935 98 1,033 P value 1.53 × 10−7
ACEI, angiotensin-converting enzyme inhibitor; AE, adverse event; ARB, angiotensin receptor blocker.
aOne homozygous for 534Gln.
Figure 2 Forest plot representing the meta-analysis association between F5 p.Arg534Gln and outcomes observed in the Vanderbilt and 
PREDICTION-ADR studies.
Summary Estimate
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with F5 Leiden (Table S6), meaning that the presence of ARB-AE 
individuals is not diluting the effect.
Studies have shown evidence for a role of the coagulation system 
in angioedema. However, no study has previously suggested a role 
for F5 variants, possibly due to a lack of statistical power.
The mechanism behind ACEI-AE and ARB-AE is not fully 
understood, but is presumed to involve an accumulation of the 
vasoactive mediators bradykinin and substance P. Activation of 
the kallikrein–kinin system contributes to the pathogenesis of 
hereditary angioedema with complement C1 esterase inhibitor 
deficiency.32 ACE (also called kininase II) catalyzes the forma-
tion of angiotensin II from angiotensin I, and is involved in the 
breakdown of the vasodilator bradykinin. ACEIs potentiate 
the effect of bradykinin through inhibition of its breakdown. 
Bradykinin acts on bradykinin receptors 1 and 2 that are im-
portant mediators of cardiovascular homeostasis. Stimulation 
of the bradykinin 2 receptor induces vasodilation and vascu-
lar permeability, and also stimulates the release of substance P 
from sensory nerve endings. Substance P increases vascular per-
meability and contributes to ACEI-AE in rodent models.33,34 
The coagulation system and genes involved have already been 
associated with accumulation of bradykinin and angioedema. 
In a subset of hereditary angioedema patients with normal 
complement C1 esterase levels and function, F12 mutations are 
reported to cause uncontrolled activity of the plasma contact 
system and massively increased production of bradykinin.35 It 
is possible that mutations in other plasma factors involved in 
coagulation and fibrinolysis may have similar effects. F5 mu-
tations are known to lead to an accumulation of fibrin. The 
most well-known example, the F5 Leiden mutation G1691A in 
exon 10, results in the conversion of arginine to glycine (p.Ar-
g534Gln). This amino acid exchange is in the site where factor 
V normally is cleaved by activated protein C. The conversion 
results in a clotting factor that remains active, since it cannot 
easily be degraded by activated protein C. This facilitates the 
overproduction of thrombin that leads to an excess of fibrin, 
which in turn limits the intercellular flow.36
Moreover, our GRS results showed an effect of rs6020 on risk 
of ACEI-AE and ARB-AE. Like F5 Leiden, this variant is associ-
ated with thrombosis.37,38 The F5 variant rs6020 is more common 
in black populations, in whom ACEI-AE is approximately three 
times more prevalent compared with other populations.16 This 
could be related to a difference in bradykinin sensitivity since black 
Americans have been shown to be more sensitive to increases in 
vascular permeability caused by bradykinin.
We aimed to replicate our results in the independent Vanderbilt 
study to confirm positive association signals and exclude possible 
false-positive results. This was, however, not possible for all asso-
ciated variants, since some variants were missing (Figure  S6). In 
addition, we would have liked to do a separate analysis for ARBs to 
see if the association signal changes. However, due to the lower in-
cidence of ARB-AE this would have been challenging. Moreover, 
Table 4 Association of nonsynonymous F5 variants (common and rare) with ACEI-AE and ARB-AE
Chromosome Position rsID REF ALT MAF P OR Location AA Changes
1 169519049 rs6025a C T 0.048 5.96E-07 2.849 exon10 Q534R
1 169511878 rs6018 T G 0.054 0.228 1.279 exon13 N817T
1 169511755 rs4524 T C 0.249 0.3177 0.895 exon13 K858R
1 169519112 rs6020b C T 0.009 0.3278 1.691 exon10 R513K
1 169500232 rs200157005c G A 0.0005 0.3727 5.054 exon15 P1667L
1 169511576 rs149389480c G C 0.0005 0.3727 5.054 exon13 P918A
1 169524542 rs143509841c T G 0.0005 0.3727 5.054 exon7 K332N
1 169511585 rs9332695 T A 0.015 0.4527 1.691 exon13 T915S
1 169541513 rs6019 C G 0.051 0.6047 0.718 exon3 D107H
1 169513569 rs140530655c C T 0.0005 1 0.56 exon12 R647H
1 169529903 chr1:169529903c C T 0.0005 1 0.56 exon4 G159R
MAF is the minor allele frequency for the combination of cases and controls.
P and OR are from single variant analysis.
AA, amino acid; ACEI, angiotensin-converting enzyme inhibitor; AE, adverse event; ALT, alternative allele; ARB, angiotensin receptor blocker; OR, odds ratio; REF, 
reference allele; rsID, reference SNP cluster ID; SNP, single nucleotide polymorphism.
aFactor V Leiden main causal variant in white European populations for deep vein thrombosis. brs6020 has a 30-fold higher frequency in African and Asian 
populations (AF = 0.3). These populations are known to be at greater risk of angioedema. cVariants are used in the SKAT-O (sequence kernel association test – 
optimal) analysis (P = 0.00209).
Table 5 Association of combined nonsynonymous F5 
variants (common and rare) with ACEI-AE and ARB-AE
F5 gene score
Odds ratio  











Individuals carrying at least one deleterious variant against none were tested 
in a model adjusted for age, sex, center, batch, and 1–10 PC.
ACEI, angiotensin-converting enzyme inhibitor; AE, adverse event; ARB, 
angiotensin receptor blocker; PC, principal components.
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we had limited power to detect rare variants with small or moder-
ate effects, or to detect even rarer variants with large effects.
In conclusion, we have identified common and rare genetic vari-
ants in the F5 gene that are associated with an increased risk of 
developing ACEI-AE or ARB-AE. These findings may have im-
portant clinical implications for the prevention of ACEI-AE and 
safer treatment of hypertension.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com).
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